منابع مشابه
Chemotherapy: which drug and when?
The treatment of advanced colorectal cancer has become very complex due to: (i) the relative efficacy of therapy, which has turned a rapidly fatal cancer into a more indolent disease in the last 10 years; (ii) the availability of four active chemotherapeutic agents and three biologics; (iii) the efficacy of several lines of therapy; (iv) the rare, but real, chance of curing stage IV patients th...
متن کاملChemotherapy in early breast cancer: when, how and which one?
The efficacy of chemotherapy depends on the level of risk of the individual patient. Because of this, careful estimation of the risk level is mandatory. In addition to well-established clinicopathological factors, validated gene expression signatures might be useful in selected patients if all other criteria are inconclusive for therapeutic decision-making. If indicated, chemotherapy can be use...
متن کاملMathematical Modeling and Lyapunov-Based Drug Administration in Cancer Chemotherapy
In this paper a new mathematical model is developed for the dynamics between tumor cells, normal cells, immune cells, chemotherapy drug concentration and drug toxicity. Then, the theorem of Lyapunov stability is applied to design treatment strategies for drug protocols that ensure a desired rate of tumor cell kill and push the system to the area with smaller tumor cells. Using of this theorem a...
متن کاملAntiphospholipid antibodies: which and when?
Antiphospholipid antibodies (aPL) are a group of autoantibodies, mainly of the IgG and IgM class, directed predominantly against negatively charged phospholipids.1-4 Several recent studies have found that patients with these antibodies are prone to repeated episodes of venous and arterial thrombosis, recurrent fetal loss, and thrombocytopenia."'5 In addition, there have been reports of the poss...
متن کاملChemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Chemotherapy-induced nausea and vomiting (CINV) remains an important and common toxicity of cancer treatment. Recent guideline revisions have classified chemotherapeutic agents into four categories of emesis risk without the use of preventive agents: high (> 90%), moderate (30%--90%), low (10%-30%), and minimal (< 10%). Currently available antiemetic agents, including corticosteroids, 5-hydroxy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2010
ISSN: 0923-7534
DOI: 10.1093/annonc/mdq293